Precision Clinical Trial Solutions: AI-Powered Patient Screening

    Identify the right patients faster, and increase recruitment by 30-40% with Kitsa's AI-powered clinical trial solution.

    The first 100 sites to register receive a $25 gift card.

    Why Precision Clinical Trial Solutions Matter for Screening Accuracy

    Manual screening methods are slow, costly, and carry a high risk of errors. AI-powered solutions enable faster, more accurate screening that improves trial outcomes.

    Time-Consuming Processes

    Sites may spend weeks reviewing records using conventional methods, delaying trial timelines.

    High Screening Failure Rates

    Manual screening leads to high error rates and missed eligible patients.

    Revenue Impact

    Screening failures and delays result in significant lost trial revenue opportunities.

    Sponsor Confidence

    Inconsistent screening accuracy affects sponsor trust and future trial opportunities.

    Kitsa's Precision Screening Technology

    Experience the power of AI-driven patient screening that delivers accurate results faster than ever before.

    AI-Powered Precision

    Advanced algorithms ensure accurate patient-to-trial matching with minimal errors.

    30-40% Faster Recruitment

    Accelerate patient identification and enrollment with intelligent automation.

    Reduced Screening Failures

    Cut screening failures by up to 80% with real-time eligibility verification.

    Regulatory Compliance

    Built-in compliance with HIPAA, 21 CFR Part 11, and other regulatory standards.

    Ready to Improve Your Screening Accuracy?

    See how Kitsa's precision screening can transform your clinical trial recruitment.

    Frequently Asked Questions

    FAQ

    Frequently asked questions

    How does intelligent site selection differ from manual feasibility?
    Manual feasibility relies on surveys and relationships; intelligent site selection uses structured data, performance history, and patient availability signals to rank sites objectively and at global scale.
    Can Kitsa support rare disease or oncology site selection?
    Yes. Kitsa is therapeutic-area aware and is widely used for oncology, rare disease, neurodegenerative, and early-phase trials where patient density and investigator expertise are critical.
    How are sites scored?
    Sites are scored on patient population fit, historical enrollment performance, investigator experience in the indication, site capacity, competitive trial load, and operational reliability.